C hronic obstructive pulmonary disease (COPD) is a major cause of disability and death throughout the world. The main goal of this educational initiative of the Canadian Thoracic Society (CTS) is to optimize early diagnosis, prevention and management of COPD in Canada.
Specialists can assist with the management of COPD patients who fail to respond to combined bronchodilator therapy, have severe or recurrent exacerbations, have complex comorbidities, require pulmonary rehabilitation, require assessment for home oxygen or may be candidates for surgical therapies (ie, lung transplantation, lung volume reduction surgery or bullectomy).
MANAGEMENT OF COPD
Key Message #8: COPD is amenable to therapy. A management strategy consisting of combined pharmacotherapy and nonpharmacotherapeutic interventions can effectively improve symptoms, activity levels and quality of life, even in patients with severe COPD. The goals of COPD management include preventing disease progression, alleviating symptoms, improving exercise tolerance, preventing and treating exacerbations, and reducing mortality. This requires a stepwise approach in which therapy is escalated based on the severity of symptoms and disability ( Figure 2 ).
Key Message #9:
Smoking cessation is the single most effective intervention to reduce the risk of developing COPD and the only intervention that has been shown to slow its progression. At least 70% of smokers visit a physician each year, and advice from a physician is quoted as an important motivator to quit. Even brief counselling lasting less than 3 min should be offered to every smoker, with the understanding that more intensive therapy (individual and group counselling, nicotine replacement and the antidepressant bupropion), which results in in the highest quitting rates, should be used whenever possible.
Key Message #10: Education of the patient and family with supervision and support based on disease-specific self-management principles is valuable. In addition to improving coping skills and quality of life, self-management plans also reduce hospitalization and health care costs. Collaboration among the patient, family and appropriately trained COPD educators is pivotal to success of education and selfmanagement plans.
Key Message #11: Vaccinations prevent exacerbations of COPD. COPD patients infected with influenza are at higher risk for hospitalization, so an annual influenza vaccine is recommended. The benefit of pneumococcal vaccine is less well established, but we recommend that COPD patients be given this vaccine at least once, and possibly every five to 10 years.
Key Message #12: Bronchodilators are the mainstay of COPD pharmacotherapy. They can reduce air trapping (lung overinflation) and dyspnea, and improve quality of life even if there is no improvement in spirometry (Figure 3) . • For patients with activity-related breathlessness and minimal disability, initial treatment should be with a short-acting beta 2 -agonist as needed (or a regular anticholinergic or combination anticholinergic/beta 2 -agonist). The choice of first-line therapy is based on clinical response and tolerance of adverse effects.
• If symptoms persist despite this, add a long-acting bronchodilator such as an anticholinergic (tiotropium 18 µg qd) or a long-acting beta 2 -agonist (LABA) (formoterol 12 µg bid or salmeterol 50 µg bid) should be added. Continue a short-acting bronchodilator as needed for immediate symptom relief.
• For patients with moderate to severe persistent symptoms, a combination of a long-acting anticholinergic and an LABA is recommended in addition to an as-needed short-acting beta 2 -agonist for immediate symptom relief.
• In patients with severe symptoms despite the use of both a long-acting anticholinergic and an LABA, a long-acting oral theophylline may be tried. Monitoring of theophylline blood levels for adverse effects and for drug interactions is necessary.
• Long term maintenance treatment with oral corticosteroids has no proven benefit in COPD and is associated with a high risk of serious adverse effects.
• Unlike asthma, inhaled corticosteroids (ICSs) should not be used as a first-line medication in COPD. However, ICSs should be considered in patients with moderate to severe COPD who experience three or more acute exacerbations per year, especially if these exacerbations require treatment with oral steroids.
• Patients who remain breathless despite optimal bronchodilator therapy may benefit from the addition of a combination of ICS/LABA, but this should be considered on an individual basis.
Key Message #13: All COPD patients should be encouraged to maintain an active lifestyle. COPD patients with activity-related shortness of breath tend to reduce activity levels to avoid precipitating respiratory discomfort. Deconditioning due to inactivity contributes to generalized skeletal muscle dysfunction so that even minor activity provokes limb fatigue. Clinically stable COPD patients who remain breathless and limited in their activity despite optimal bronchodilators should be referred to an exercise training program. Formal pulmonary rehabilitation programs that include supervised exercise training and patient education have been shown to consistently improve breathlessness, exercise endurance and quality of life, and may reduce emergency visits and hospitalizations in patients with COPD.
Key Message #14: Acute exacerbations of COPD (AECOPD) are the most frequent cause of medical visits, hospitalizations and death among COPD patients. AECOPD is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medications and/or supplementation with additional medications. AECOPD is further classified as either purulent or nonpurulent. Antibiotics should only be considered in patients with purulent AECOPD. History, physical examination and chest x-rays are recommended for patients with AECOPD. Sputum Gram stain and culture should be considered for patients with very poor lung function, those with frequent exacerbations or those who have been on antibiotics in the previous three months. Spirometry should be completed in patients suspected of having COPD only after recovery and when they are stable.
• Combination therapy with short-acting beta 2 -agonists and anticholinergic bronchodilators should be used to treat dyspnea in AECOPD. Patients already on an oral methylxanthine may continue this therapy during AECOPD, but there is no role for the new initiation of therapy.
• Oral or intravenous steroids should be administered for 14 days in most moderate to severe COPD patients with AECOPD; however, shorter treatment periods of between seven and 14 days may also be effective. Doses equivalent to 25 to 50 mg of prednisone per day are recommended.
• Antibiotics are beneficial in severe AECOPD, which are episodes associated with increased dyspnea and increased sputum purulence or volume. Patients with simple AECOPD ( 
